

May 21, 2012

IN RESPONSE, PLEASE
REFER TO: M120511B

MEMORANDUM TO: R. W. Borchardt
Executive Director for Operations

FROM: Annette Vietti-Cook, Secretary */RA/*

SUBJECT: STAFF REQUIREMENTS – BRIEFING ON POTENTIAL
MEDICAL ISOTOPE PRODUCTION LICENSING ACTIONS, 9:00
A.M., FRIDAY, MAY 11, 2012, COMMISSIONERS'
CONFERENCE ROOM, ONE WHITE FLINT NORTH,
ROCKVILLE, MARYLAND (OPEN TO PUBLIC ATTENDANCE)

The Commission was briefed by the NRC staff on the status of efforts for potential medical isotope production licensing actions. A panel of external stakeholders also briefed the Commission. Parrish Staples, Director of the Office of European and African Threat Reduction, Department of Energy, National Nuclear Security Agency (DOE/NNSA) discussed DOE/NNSA's efforts, as well as the Interagency Working Group's efforts, to support the domestic production of Mo-99. Randy Spickard, Vice President of Corporate Development, Babcock & Wilcox Technical Services Group, Inc., Carmen I. Bigles, President and Chief Executive Officer, Coqui Radiopharmaceuticals Corporation, and Gregory Piefer, Chief Executive Officer, SHINE Medical Technologies, Inc., discussed their organizations' status for the production of Mo-99.

Subsequent to the meeting, on May 15, 2012, the staff provided the technical differences between the interim staff guidance for aqueous homogeneous reactors and production facilities and the guidance in NUREG-1537.

cc: Chairman Jaczko
Commissioner Svinicki
Commissioner Apostolakis
Commissioner Magwood
Commissioner Ostendorff
OGC
CFO
OCA
OIG
OPA
Office Directors, Regions, ACRS, ASLBP (via E-Mail)
PDR